<DOC>
	<DOC>NCT00626743</DOC>
	<brief_summary>To assess the pharmacodynamic effects of co-administrated SK3530 (PDE5 inhibitor) and Amlodipine, phase I study in Hypertensive patient was designed.</brief_summary>
	<brief_title>Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male subjects 1965 years of age inclusive Subjects with hypertension as defined 100 mmHg ≤ SBP&lt;140 mmHg and 65 mmHg ≤ DBP &lt; 90 mmHg after more than 5 minutes in the supine position Written informed consent Willing and able to comply with the requirements of the protocol Subjects with acute or chronic disease within 4 weeks of study initiation. Subejcts with any gastrointestinal disorders known to alter drug absorption(except appendectomy, herniotomy, etc.) Subjects with any clinically significant allergic disease or with a known allergy to the PDE5 inhibitors Subjects with clinically significant abnormalities on laboratory tests Subjects with orthostatic hypotension defined as a fall in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg when a person assumes a standing position Subjects with abnormal QTc interval(≥440ms) Subjects with colorblindness or weakness Subejcts with alcohol, drug or caffeine abuse Diet known to alter drug absorption, distribution, metabolism or elimination processes Subjects who participated in other clinical studies within 2 months before an administration Other subjects who are ineligible for the study at the discretion of the principle investigator or subinvestigators</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>